Overview

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Status:
Not yet recruiting

Trial end date:
2026-01-10

Target enrollment:

Participant gender:

Summary

This is a randomized, multicenter, two-arm, noncomparative, phase II study of fluzoparib with or without apatinib for maintenance therapy in PARPi-pretreated platinum-sensitive recurrent ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib with or without apatinib.

Phase:

Phase 2

Details

Lead Sponsor:

Guangxi Medical University

Treatments:

Apatinib
Fluzoparib